Status:
UNKNOWN
Vasoreactivity in Carriers of Genetic Polymorphisms
Lead Sponsor:
Heidelberg University
Conditions:
Healthy
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on ve...
Detailed Description
Study I: Using the dorsal hand vein compliance technique dose-response curves to bradykinin and sodium nitroprusside will be obtained in healthy volunteers during preconstriction with phenylephrine an...
Eligibility Criteria
Inclusion
- age: 18 - 70
- gender: male
- good state of health
Exclusion
- known condition causing endothelial dysfunction (e.g. diabetes, hyperlipidaemia, arterial hypertension, smoking, homocysteinemia)
- regular medication and/or treatment with drugs within the last 4-6 weeks (exclusion has to be decided in each case)
- acute or chronic illness
- methylxanthines and alcohol during 12 hours before the study
- nicotine during 1 year before the study
- drug and/or alcohol abuse
- pregnancy or lactation
Key Trial Info
Start Date :
November 1 1999
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00160888
Start Date
November 1 1999
End Date
December 1 2006
Last Update
September 12 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Internal Medicine VI
Heidelberg, Baden-Wurttemberg, Germany, 69120